MedTrace Logo

Fasting Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg

NCT00649571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-04-24

No results posted yet for this study

Summary

The objective of this study was to investigate the bioequivalence of Mylan's doxycycline monohydrate 100 mg tablets to Par's Adoxa® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administered under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Doxycycline Monohydrate Tablets (100 mg

100mg, single dose fasting

DRUG

Adoxa Tablets 100 mg

100mg, single dose fasting

Sponsors & Collaborators

  • Mylan Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Dorian Williams, M.D. · Kendle International Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00649571 on ClinicalTrials.gov